Ranking Invest

Summit Therapeutics Inc.

Segmento: Healthcare Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Indicadores Básicos

Valor de Mercado

$ 18.69 Bi

IVR

-0.03

IVR2

-0.05

Índices de Previsibilidade

Faturamento

1.49

Lucro

0.35

Margem

1.27

Índices de Tendência

Faturamento

-7.60

Lucro

-10.31

Margem

7.85

Índices de Endividamento

DIV/PAT

-0.60

DIV/L4T

0.85

Dívida Líquida

-$ 205.08 Mi

Patrimônio Líquido

$ 344.33 Mi

L4T

-$ 240.75 Mi

MM4T

0.00%

Dívidas
Dividendos
Cotação: $25.35

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre